NRX Pharmaceuticals Inc.-CW22NRXPWPreferred / convertible
13F holders, Q1 2026 (March 31)2holders −1
0new positions
1sold out
$0.01avg. 13F price*
At the end of Q1 2026, 2 institutions reported holding NRX Pharmaceuticals Inc.-CW22 (NRXPW) in their 13F filings, down 1 from Q4 2025. 0 opened new positions and 1 sold out. The largest holders were Wolverine Asset Management LLC ($347) and UBS Group AG ($0).
- Company
- NRX Pharmaceuticals Inc.-CW22
- CUSIP
- 629444118
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $669 |
All 13F filers, Q4 2025 → Q1 2026: 1,300 shares bought and 13,251 shares sold, net −11,951 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Wolverine Asset Management LLC | — | Add +5.8% | 23,593 | $347 |
| UBS Group AG | — | Reduce -99.3% | 13 | $0 |
"% of holder's portfolio" is NRXPW's weight in each manager's 13F, not the share of NRX Pharmaceuticals Inc.-CW22 the manager owns.